Related Experiment Video
Updated: Apr 1, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Depression as a microglial disease
Raz Yirmiya1, Neta Rimmerman1, Ronen Reshef1
1Department of Psychology, The Hebrew University of Jerusalem, Jerusalem 91905, Israel.
Abstract:
Despite decades of intensive research, the biological mechanisms that causally underlie depression are still unclear, and therefore the development of novel effective antidepressant treatments is hindered. Recent studies indicate that impairment of the normal structure and function of microglia, caused by either intense inflammatory activation (e.g., following infections, trauma, stroke, short-term stress, autoimmune or neurodegenerative diseases) or by decline and senescence of these cells (e.g., during aging, Alzheimer's disease, or chronic unpredictable stress exposure), can lead to depression and associated impairments in neuroplasticity and neurogenesis. Accordingly, some forms of depression can be considered as a microglial disease (microgliopathy), which should be treated by a personalized medical approach using microglial inhibitors or stimulators depending on the microglial status of the depressed patient.
Insights
Depression may stem from impaired microglia, the brain's immune cells. Treating this "microgliopathy" with targeted therapies could offer new hope for effective depression treatment.
Area of Science:
- Neuroscience
- Immunology
- Psychiatry
Background:
- The precise biological mechanisms of depression remain elusive, hindering novel antidepressant development.
- Emerging research links depression to impaired microglial function, affecting neuroplasticity and neurogenesis.
- Microglial dysfunction can arise from inflammation or senescence, impacting brain health.
Purpose of the Study:
- To explore the role of microglia in the pathophysiology of depression.
- To propose a novel perspective of depression as a microglial disease (microgliopathy).
- To suggest a personalized treatment approach for depression based on microglial status.
Main Methods:
- Review of recent scientific literature on microglia and depression.
- Analysis of conditions leading to microglial impairment (inflammation, senescence).
- Correlation of microglial status with neuroplasticity and neurogenesis deficits.
Main Results:
- Microglial impairment, due to inflammation or aging, is associated with depression.
- Altered microglia can disrupt neuroplasticity and neurogenesis, contributing to depressive symptoms.
- Certain depression forms may be classified as microgliopathies.
Conclusions:
- Depression can be viewed as a microglial disease, or microgliopathy.
- Personalized medicine targeting microglial function (inhibition or stimulation) is a promising avenue for depression treatment.
- Understanding microglial status is key to developing effective, individualized antidepressant strategies.
More Related Videos
10:40Immunofluorescence Staining Using IBA1 and TMEM119 for Microglial Density, Morphology and Peripheral Myeloid Cell Infiltration Analysis in Mouse Brain
Published on: October 27, 2019
07:54Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
Published on: April 13, 2017
Related Concept Videos
01:18Depression: Overview
01:05Long-term Depression
01:27Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...